MedTrace Logo

A Study to Evaluate the Efficacy and Safety of Itolizumab in Subjects Hospitalized With COVID-19

NCT04605926 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2026-05-12

No results posted yet for this study

Summary

This is a randomized controlled trial to evaluate the efficacy and safety of itolizumab in subjects hospitalized with COVID-19.

Conditions

  • Coronavirus

Interventions

BIOLOGICAL

EQ001

itolizumab \[Bmab600\]

BIOLOGICAL

EQ001 Placebo

EQ001 Placebo

Sponsors & Collaborators

  • Biocon Limited

    lead INDUSTRY

Principal Investigators

  • Maple Fung, MD · Equillium

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-30
Primary Completion
2021-04-30
Completion
2021-06-30
FDA Drug
Yes

Countries

  • Colombia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04605926 on ClinicalTrials.gov